In order to access this content you must be logged in and have a subscription to PL Intelligence.
PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Cyclacel announces in-licensing of phase I anticancer drug from Sankyo
Cyclacel and Xcyte Therapies combine to form international biopharmaceutical company
CYCLACEL AND ALTANA PHARMA ANNOUNCE COLLABORATION ON MITOTIC TARGET IDENTIFICATION
CYCLACEL ANNOUNCES COLLABORATION ON NEPHROLOGY APPLICATIONS OF CDK INHIBITORS
Lorus and Cyclacel Limited enter into licensing agreement
VIA Pharmaceuticals Announces Grant of New Patent Rights - Phosphodiesterase Inhibitors
Progen granted patent for anti-cancer and anti-thrombotic drug
Aphios is granted US liposome patent
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
